Clinical Trial Update: Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating panobinostat with high-dose gemcitabine/busulfan/melphalan and autologous stem cell transplant for refractory/relapsed lymphoma has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Gemcitabine (Gemcitabine)
• Melphalan (Melphalan)
• Panobinostat (Panobinostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN